Drugs / CK0801
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03773328 | Nov 2022 → Feb 2025 | Guillain-Barre syndrome | Cellenkos, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT04468971 | Sep 2020 → Oct 2021 | COVID-19, acute respiratory distress syndrome | Cellenkos, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03773393 | May 2019 → May 2027 expected | bone marrow disorder | Cellenkos, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07576699 | Jul 2026 → Jun 2028 expected | graft versus host disease | Cellenkos, Inc. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07499102 | Aug 2026 → Aug 2028 expected | aplastic anemia | Cellenkos, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CK0801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07499102 ↗ |
| Known as | CK0802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07576699 ↗ |
| Modality | Cell therapy | “CK0801 (a cord-blood derived T-regulatory cell product)” NCT03773328 ↗ |
| Route | Intravenous | “one 50mL intravenous dose of CK0801” NCT03773328 ↗ |